½ÃÀ庸°í¼­
»óǰÄÚµå
1753889

Áö³ëŸÀÌÇÎ ½ÃÀå º¸°í¼­ : Á¦Ç° ¹× ¼­ºñ½º, ±â¼ú, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ªº°(2025-2033³â)

Genotyping Market Report by Product and Service, Technology (Polymerase Chain Reaction, Capillary Electrophoresis, Microarray, Sequencing, Mass Spectrometry, and Others), Application, End User, and Region 2025-2033

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: IMARC | ÆäÀÌÁö Á¤º¸: ¿µ¹® 145 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è Áö³ëŸÀÌÇÎ ½ÃÀå ±Ô¸ð´Â 2024³â 219¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº 2033³â±îÁö 633¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óÇϸç, 2025³âºÎÅÍ 2033³â±îÁö 11.90%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» º¸ÀÏ °ÍÀ¸·Î Àü¸ÁÇϰí ÀÖ½À´Ï´Ù.

Áö³ëŸÀÌÇÎÀº Àΰ£, ½Ä¹°, µ¿¹°, ¹Ì»ý¹°À» Æ÷ÇÔÇÑ »ý¹°ÀÇ À¯ÀüÀÚÇü¿¡¼­ À¯ÀüÀû üÁúÀ» °áÁ¤Çϱâ À§ÇØ DNA ¿°±â¼­¿­À» Á¶»çÇÏ´Â ºÐ¼®ÀýÂ÷¸¦ ¸»ÇÕ´Ï´Ù. À¯ÀüÀÚ °Ë»ç¿¡¼­´Â DNA ±¸Á¶ÀÇ º¯È­³ª ÀÏ¿°±â ´ÙÇü¼º µî ´Ù¾çÇÑ À¯ÀüÀû º¯À̸¦ °Ë»çÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ Á¤º¸¸¦ Ȱ¿ëÇÏ¸é °³ÀÎÀÇ À¯Àü·Â¿¡ ´ëÇÑ µ¥ÀÌÅ͸¦ Á¦°øÇϸ鼭 °³ÀÎ °£ Â÷À̸¦ ºñ±³ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÇÑÆí, ¹ÙÀÌ·¯½º³ª ¼¼±Õ°ú °°Àº ¹Ì»ý¹°ÀÇ Áö³ëŸÀÌÇÎÀº ¹ÙÀÌ·¯½º³ª ¼¼±Õ¼º ÁúȯÀÇ ¹ß»ý¿øÀ» ÆÄ¾ÇÇÏ¿© º´¿øÃ¼ÀÇ È®»êÀ» ¸·´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.

Áö³ëŸÀÌÇÎ ½ÃÀå µ¿Çâ:

¼¼°è ½ÃÀåÀº Àü ¼¼°è ÀÇ·á ½Ã¼³¿¡¼­ À¯ÀüÀÚÇü ±â¹Ý Áø´Ü °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡°¡ ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ±× ¹è°æ¿¡´Â ¾Ï°ú À¯Àü¼º ÁúȯÀ» Æ÷ÇÔÇÑ ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡°¡ ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ½Å¾à °³¹ß ¹× ½ÃÀå °³Ã´ °úÁ¤¿¡¼­ µ¥ÀÌÅÍ ºÐ¼® ¹× ¾à¸®À¯ÀüüÇÐ ºÐ¾ß¿¡¼­ ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º ¼Ö·ç¼ÇÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, À¯Àüü ½Å¾à°³¹ß ¹× Á¤¹ÐÀÇ·á ¿¬±¸¿¡ ÃÊÁ¡À» ¸ÂÃá ¿¬±¸°³¹ß(R&D) Ȱµ¿¿¡ ´ëÇÑ ÅõÀÚ°¡ Å©°Ô Áõ°¡Çϰí ÀÖ´Â °Íµµ ½ÃÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù. À̿ʹ º°µµ·Î, Àü ¼¼°èÀûÀ¸·Î À¯Àüü °Ë»ç·®ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ½Ã¾à¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ½ÃÀå Àü¸ÁÀ» ¹à°Ô Çϰí ÀÖ½À´Ï´Ù. ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÏ´Â ´Ù¸¥ ¿äÀÎÀ¸·Î´Â ¸¹Àº Áúº´À» ¾Î°í ÀÖ´Â ³ëÀÎ Àα¸ÀÇ Áõ°¡, Áö³ëŸÀÌÇÎ Á¦Ç°ÀÇ Áö¼ÓÀûÀÎ ±â¼ú ¹ßÀü, ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ´ëÁßÀÇ ÀÎ½Ä Áõ°¡, ÀÇ·áºñ ÁöÃâÀÇ ´ëÆøÀûÀÎ Áõ°¡ µîÀÌ ÀÖ½À´Ï´Ù.

º» º¸°í¼­¿¡¼­ ´Ù·ç´Â ÁÖ¿ä Áú¹®

  • ¼¼°è Áö³ëŸÀÌÇÎ ½ÃÀåÀº Áö±Ý±îÁö ¾î¶»°Ô º¯È­Çؿ԰í, ¾ÕÀ¸·Î ¾î¶»°Ô º¯È­ÇØ ³ª°¥ °ÍÀΰ¡?
  • COVID-19°¡ Àü ¼¼°è Áö³ëŸÀÌÇÎ ½ÃÀå¿¡ ¹ÌÄ£ ¿µÇâÀº?
  • ÁÖ¿ä Áö¿ª ½ÃÀåÀ̶õ?
  • Á¦Ç° ¹× ¼­ºñ½ºº° ½ÃÀå ÇöȲÀº?
  • ±â¼úº° ½ÃÀå ºÐ¼®Àº?
  • ¿ëµµº° ½ÃÀå ºÐ¼®Àº?
  • ÃÖÁ¾»ç¿ëÀÚº° ½ÃÀå ºÐ¼®Àº ¾î¶»°Ô µÇ´Â°¡?
  • »ê¾÷ °¡Ä¡»ç½½ÀÇ ´Ù¾çÇÑ ´Ü°è´Â ¹«¾ùÀΰ¡?
  • ¾÷°èÀÇ ÁÖ¿ä ÃËÁø¿äÀΰú °úÁ¦´Â ¹«¾ùÀΰ¡?
  • ¼¼°è Áö³ëŸÀÌÇÎ ½ÃÀåÀÇ ±¸Á¶¿Í ÁÖ¿ä Ç÷¹À̾î´Â?
  • ¾÷°è ³» °æÀïÀº ¾î´À Á¤µµÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

  • Á¶»ç ¸ñÀû
  • ÀÌÇØ°ü°èÀÚ
  • µ¥ÀÌÅÍ ¼Ò½º
    • 1Â÷ Á¤º¸
    • 2Â÷ Á¤º¸
  • ½ÃÀå ÃßÁ¤
    • »óÇâ½Ä Á¢±Ù
    • ÇÏÇâ½Ä Á¢±Ù
  • Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼Ò°³

  • °³¿ä
  • ÁÖ¿ä ¾÷°è µ¿Çâ

Á¦5Àå ¼¼°èÀÇ Áö³ëŸÀÌÇÎ ½ÃÀå

  • ½ÃÀå °³¿ä
  • ½ÃÀå ½ÇÀû
  • COVID-19ÀÇ ¿µÇâ
  • ½ÃÀå ¿¹Ãø

Á¦6Àå ½ÃÀå ³»¿ª : Á¦Ç° ¹× ¼­ºñ½ºº°

  • ±â±â
  • ½Ã¾à°ú ŰƮ
  • ¼ÒÇÁÆ®¿þ¾î¿Í ¼­ºñ½º

Á¦7Àå ½ÃÀå ³»¿ª : ±â¼úº°

  • ÁßÇÕÈ¿¼Ò ¿¬¼â ¹ÝÀÀ(PCR)
  • ¸ð¼¼°ü Àü±â¿µµ¿
  • ¸¶ÀÌÅ©·Î¾î·¹ÀÌ
  • ½ÃÄö½Ì
  • Áú·® ºÐ¼®
  • ±âŸ

Á¦8Àå ½ÃÀå ³»¿ª : ¿ëµµº°

  • ¾à¹°À¯ÀüüÇÐ
  • Áø´Ü°ú ¸ÂÃãÇü ÀÇ·á
  • ³ó¾÷ ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö
  • µ¿¹° À¯ÀüÇÐ
  • ±âŸ

Á¦9Àå ½ÃÀå ³»¿ª : ÃÖÁ¾»ç¿ëÀÚº°

  • Á¦¾àȸ»ç ¹× ¹ÙÀÌ¿ÀÀǾàǰ ȸ»ç
  • Áø´Ü ¹× Á¶»ç ½ÇÇè½Ç
  • Çмú±â°ü
  • ±âŸ

Á¦10Àå ½ÃÀå ³»¿ª : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • Àεµ³×½Ã¾Æ
    • ±âŸ
  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ·¯½Ã¾Æ
    • ±âŸ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ½ÃÀå ³»¿ª : ±¹°¡º°

Á¦11Àå SWOT ºÐ¼®

  • °³¿ä
  • °­Á¡
  • ¾àÁ¡
  • ±âȸ
  • À§Çù

Á¦12Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦13Àå Porter's Five Forces ºÐ¼®

  • °³¿ä
  • ±¸¸ÅÀÚÀÇ ±³¼··Â
  • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
  • °æÀï Á¤µµ
  • ½Å±Ô Âü¿©¾÷üÀÇ À§Çù
  • ´ëüǰÀÇ À§Çù

Á¦14Àå °¡°Ý ºÐ¼®

Á¦15Àå °æÀï ±¸µµ

  • ½ÃÀå ±¸Á¶
  • ÁÖ¿ä ±â¾÷
  • ÁÖ¿ä ±â¾÷ °³¿ä
    • Agilent Technologies Inc.
    • Bio-Rad Laboratories Inc.
    • Danaher Corporation
    • Eurofins Scientific SE
    • F. Hoffmann-La Roche AG
    • Illumina Inc.
    • Laboratory Corporation of America Holdings
    • Qiagen N.V
    • Standard BioTools Inc.
    • Thermo Fisher Scientific Inc.
ksm

The global genotyping market size reached USD 21.9 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 63.3 Billion by 2033, exhibiting a growth rate (CAGR) of 11.90% during 2025-2033.

Genotyping refers to an analytical procedure that examines DNA sequences to determine the genetic constitution in the genotypes of living organisms, including humans, plants, animals, and microorganisms. Genetic tests enable scientists to examine a variety of genetic deviations, such as changes in DNA structure and single nucleotide polymorphisms, by detecting genetic differences through biological assays. By using this information, the differences between individuals can be compared while providing data related to the genetic history of an individual. Genotyping of microorganisms, such as viruses and bacteria, on the other hand, helps prevent the spread of pathogens by pinpointing the source of viral and bacterial diseases.

Genotyping Market Trends:

The global market is majorly driven by the rising demand for genotypic-based diagnostic testing in healthcare facilities across the globe. This can be attributed to the increasing prevalence of chronic diseases, including cancer and genetic disorders. In addition to this, the rising adoption of bioinformatics solutions in data analysis and pharmacogenomics in the drug discovery and development processes is also providing an impetus to the market growth. The market is further driven by the substantial rise in investments in research and development (R&D) activities focusing on genomic drug development and precision medicine research. Apart from this, the escalating demand for reagents for the augmenting volumes of genotyping tests on the global level is creating a positive outlook for the market. Some of the other factors that are contributing to the growth of the market include the rising geriatric population that is susceptible to developing numerous medical conditions, continual technological advancements in genotyping products, the growing awareness regarding personalized medicines among the masses and a considerable expansion of healthcare expenditure.

Key Market Segmentation:

Breakup by Product and Service:

  • Instruments
  • Reagents and Kits
  • Software and Services

Breakup by Technology:

  • Polymerase Chain Reaction (PCR)
  • Capillary Electrophoresis
  • Microarray
  • Sequencing
  • Mass Spectrometry
  • Others

Breakup by Application:

  • Pharmacogenomics
  • Diagnostics and Personalized Medicine
  • Agricultural Biotechnology
  • Animal Genetics
  • Others

Breakup by End User:

  • Pharmaceutical and Biopharmaceutical Companies
  • Diagnostics and Research Laboratories
  • Academic Institutes
  • Others

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Agilent Technologies Inc., Bio-Rad Laboratories Inc., Danaher Corporation, Eurofins Scientific SE, F. Hoffmann-La Roche AG, Illumina Inc., Laboratory Corporation of America Holdings, Qiagen N.V, Standard BioTools Inc. and Thermo Fisher Scientific Inc.

Key Questions Answered in This Report:

  • How has the global genotyping market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global genotyping market?
  • What are the key regional markets?
  • What is the breakup of the market based on the product and service?
  • What is the breakup of the market based on the technology?
  • What is the breakup of the market based on the application?
  • What is the breakup of the market based on the end user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global genotyping market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Genotyping Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product and Service

  • 6.1 Instruments
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Reagents and Kits
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Software and Services
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Technology

  • 7.1 Polymerase Chain Reaction (PCR)
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Capillary Electrophoresis
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Microarray
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Sequencing
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Mass Spectrometry
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Pharmacogenomics
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Diagnostics and Personalized Medicine
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Agricultural Biotechnology
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Animal Genetics
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Others
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Pharmaceutical and Biopharmaceutical Companies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Diagnostics and Research Laboratories
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Academic Institutes
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Agilent Technologies Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Bio-Rad Laboratories Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Danaher Corporation
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
    • 15.3.4 Eurofins Scientific SE
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
    • 15.3.5 F. Hoffmann-La Roche AG
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
    • 15.3.6 Illumina Inc.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Laboratory Corporation of America Holdings
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
    • 15.3.8 Qiagen N.V
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
    • 15.3.9 Standard BioTools Inc.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
    • 15.3.10 Thermo Fisher Scientific Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦